OBJECTIVE: To investigate the relation between the 389A/G polymorphism in the human beta 1-adrenergic receptor and acute myocardial infarction (AMI). METHODS: Polymerase chain reaction amplification and restriction fragment length polymorphism analysis were used to detect the genotypes of 150 patients with AMI and 150 age- and sex- matched control subjects, and relative clinical data were obtained. A case-control study and multiple Logistic regression analysis were performed to assess the association between 389A/G polymorphism and AMI. RESULTS: The distributions of the genotypes and allele frequencies were significantly different between two groups (P< 0.01). The prevalence of the A allele was significantly higher in patients with AMI than in control subjects. In the multivariate regression analysis, the 389A/G polymorphism (OR: 2.88, 95%CI: 1.70-4.88, P< 0.01), smoking(OR: 2.72, 95%CI: 1.52-4.88, P< 0.01), hyperlipidemia (OR: 2.85, 95%CI: 1.68-4.86, P< 0.01), diabetes mellitus(OR: 2.38, 95%CI: 1.27-4.47, P< 0.01) and hypertension (OR: 2.00, 95%CI: 1.62-3.45, P< 0.05) were independent risk factors of AMI. CONCLUSION: The 389A/G polymorphism in the human beta 1-adrenergic receptor is associated with AMI and is an independent risk factor of AMI.
OBJECTIVE: To investigate the relation between the 389A/G polymorphism in the humanbeta 1-adrenergic receptor and acute myocardial infarction (AMI). METHODS: Polymerase chain reaction amplification and restriction fragment length polymorphism analysis were used to detect the genotypes of 150 patients with AMI and 150 age- and sex- matched control subjects, and relative clinical data were obtained. A case-control study and multiple Logistic regression analysis were performed to assess the association between 389A/G polymorphism and AMI. RESULTS: The distributions of the genotypes and allele frequencies were significantly different between two groups (P< 0.01). The prevalence of the A allele was significantly higher in patients with AMI than in control subjects. In the multivariate regression analysis, the 389A/G polymorphism (OR: 2.88, 95%CI: 1.70-4.88, P< 0.01), smoking(OR: 2.72, 95%CI: 1.52-4.88, P< 0.01), hyperlipidemia (OR: 2.85, 95%CI: 1.68-4.86, P< 0.01), diabetes mellitus(OR: 2.38, 95%CI: 1.27-4.47, P< 0.01) and hypertension (OR: 2.00, 95%CI: 1.62-3.45, P< 0.05) were independent risk factors of AMI. CONCLUSION: The 389A/G polymorphism in the humanbeta 1-adrenergic receptor is associated with AMI and is an independent risk factor of AMI.
Authors: Celia Aradillas-Garc X Cd; Miguel Cruz; Elva Pérez-Luque; María E Garay-Sevilla; Juan M Malacara; Aduna R; Jesús Peralta; Ana Burguete-García; Jorge A Alegría-Torres Journal: J Biomed Res Date: 2016-10-17